Research programme: neurodegenerative disorders therapeutics - Horizon Therapeutics plc/Roche
Latest Information Update: 06 Nov 2023
Price :
$50 *
At a glance
- Originator Roche
- Developer Raptor Pharmaceutical Corp; Roche
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
- 12 Aug 2014 No development reported - Preclinical for Neurodegenerative disorders in USA (IV)
- 30 Sep 2009 TorreyPines Therapeutics Inc has merged with Raptor Pharmaceuticals Corp to form Raptor Pharmaceutical Corp